|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US3710795A
(en)
|
1970-09-29 |
1973-01-16 |
Alza Corp |
Drug-delivery device with stretched, rate-controlling membrane
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
DE3474511D1
(en)
|
1983-11-01 |
1988-11-17 |
Terumo Corp |
Pharmaceutical composition containing urokinase
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4863457A
(en)
|
1986-11-24 |
1989-09-05 |
Lee David A |
Drug delivery device
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
AU4308689A
(en)
|
1988-09-02 |
1990-04-02 |
Protein Engineering Corporation |
Generation and selection of recombinant varied binding proteins
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5164188A
(en)
|
1989-11-22 |
1992-11-17 |
Visionex, Inc. |
Biodegradable ocular implants
|
|
US5780225A
(en)
|
1990-01-12 |
1998-07-14 |
Stratagene |
Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
|
|
AU7247191A
(en)
|
1990-01-11 |
1991-08-05 |
Molecular Affinities Corporation |
Production of antibodies using gene libraries
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5698426A
(en)
|
1990-09-28 |
1997-12-16 |
Ixsys, Incorporated |
Surface expression libraries of heteromeric receptors
|
|
KR0185215B1
(ko)
|
1990-11-30 |
1999-05-01 |
요시다 쇼오지 |
서방성 안구삽입용 약제
|
|
WO1992009690A2
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with altered binding properties
|
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
|
ATE414768T1
(de)
|
1991-04-10 |
2008-12-15 |
Scripps Research Inst |
Bibliotheken heterodimerer rezeptoren mittels phagemiden
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
ES2227512T3
(es)
|
1991-12-02 |
2005-04-01 |
Medical Research Council |
Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
|
|
WO1993015722A1
(en)
|
1992-02-07 |
1993-08-19 |
Syntex (Usa) Inc. |
Controlled delivery of pharmaceuticals from preformed porous microparticles
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
ATE452975T1
(de)
|
1992-08-21 |
2010-01-15 |
Univ Bruxelles |
Immunoglobuline ohne leichte ketten
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
ATE204325T1
(de)
|
1993-04-29 |
2001-09-15 |
Unilever Nv |
Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
|
|
EP0714409A1
(en)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Antibodies
|
|
JPH09506262A
(ja)
|
1993-12-08 |
1997-06-24 |
ジェンザイム・コーポレイション |
特異的抗体の製造方法
|
|
PT1231268E
(pt)
|
1994-01-31 |
2005-11-30 |
Univ Boston |
Bancos de anticorpos policlonais
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5516637A
(en)
|
1994-06-10 |
1996-05-14 |
Dade International Inc. |
Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
CA2229043C
(en)
|
1995-08-18 |
2016-06-07 |
Morphosys Gesellschaft Fur Proteinoptimierung Mbh |
Protein/(poly)peptide libraries
|
|
JP2978435B2
(ja)
|
1996-01-24 |
1999-11-15 |
チッソ株式会社 |
アクリロキシプロピルシランの製造方法
|
|
WO1997042217A1
(en)
|
1996-05-06 |
1997-11-13 |
The Uab Research Foundation |
Radiolabeled fusion toxins for cancer therapy
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
US6995259B1
(en)
|
1998-10-23 |
2006-02-07 |
Sirna Therapeutics, Inc. |
Method for the chemical synthesis of oligonucleotides
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
WO2001014424A2
(en)
|
1999-08-24 |
2001-03-01 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
KR20030032922A
(ko)
|
2000-02-24 |
2003-04-26 |
싸이트 테라피스 인코포레이티드 |
세포의 동시 자극 및 농축
|
|
WO2003052121A2
(en)
|
2001-12-17 |
2003-06-26 |
Beth Israel Deaconess Medical Center |
Method of reducing angiogenesis
|
|
US7595048B2
(en)
|
2002-07-03 |
2009-09-29 |
Ono Pharmaceutical Co., Ltd. |
Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
|
|
US8685435B2
(en)
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
|
RS54271B1
(sr)
|
2005-07-01 |
2016-02-29 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP2500352A1
(en)
|
2005-08-19 |
2012-09-19 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
NZ582150A
(en)
|
2007-06-18 |
2012-08-31 |
Msd Oss Bv |
Antibodies to human programmed death receptor pd-1
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
EP3753947A1
(en)
|
2007-09-14 |
2020-12-23 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
DK2238170T3
(en)
*
|
2008-01-31 |
2017-02-27 |
Inserm - Inst Nat De La Santé Et De La Rech Médicale |
ANTIBODIES AGAINST HUMAN CD39 AND ITS USE FOR INHIBITING ACTIVITY OF T-REGULATORY CELLS
|
|
GB0906579D0
(en)
|
2009-04-16 |
2009-05-20 |
Vernalis R&D Ltd |
Pharmaceuticals, compositions and methods of making and using the same
|
|
CN102203132A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂的组合物和使用方法
|
|
CN102203125A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂及其使用方法
|
|
HRP20170908T1
(hr)
|
2008-12-09 |
2017-09-22 |
F. Hoffmann - La Roche Ag |
Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
|
|
EP2210891A1
(en)
|
2009-01-26 |
2010-07-28 |
Domain Therapeutics |
New adenosine receptor ligands and uses thereof
|
|
EP2408775B1
(en)
|
2009-03-20 |
2015-06-17 |
SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. |
Oxidated derivatives of triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
|
|
JP2013512251A
(ja)
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
|
|
HUE028640T2
(en)
|
2010-02-05 |
2016-12-28 |
Heptares Therapeutics Ltd |
1,2,4-triazin-4-amine derivative
|
|
ES2365960B1
(es)
|
2010-03-31 |
2012-06-04 |
Palobiofarma, S.L |
Nuevos antagonistas de los receptores de adenosina.
|
|
KR20130060223A
(ko)
*
|
2010-05-04 |
2013-06-07 |
메리맥 파마슈티컬즈, 인크. |
상피세포 성장인자 수용체(ｅｇｆｒ)에 대한 항체 및 이의 용도
|
|
JP6266343B2
(ja)
|
2010-07-16 |
2018-01-24 |
アディマブ， エルエルシー |
抗体ライブラリー
|
|
DK2654789T3
(en)
|
2010-12-22 |
2018-09-03 |
Orega Biotech |
ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF
|
|
RS61033B1
(sr)
|
2011-11-28 |
2020-12-31 |
Merck Patent Gmbh |
Antitela na pd-l1 i njihova upotreba
|
|
CA2873402C
(en)
|
2012-05-15 |
2023-10-24 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
DK3089994T3
(da)
|
2013-12-30 |
2022-07-04 |
Epimab Biotherapeutics Inc |
Fabs-in-tandem-immunglobulin og anvendelser deraf
|
|
CA2936244A1
(en)
|
2014-01-21 |
2015-07-30 |
Medimmune, Llc |
Compositions and methods for modulating and redirecting immune responses
|
|
US9300829B2
(en)
|
2014-04-04 |
2016-03-29 |
Canon Kabushiki Kaisha |
Image reading apparatus and correction method thereof
|
|
SI3888674T1
(sl)
|
2014-04-07 |
2024-08-30 |
Novartis Ag |
Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
|
|
EP3215538A4
(en)
*
|
2014-11-07 |
2018-07-04 |
Igenica Biotherapeutics, Inc. |
Anti-cd39 antibodies and uses thereof
|
|
HK1246304A1
(zh)
|
2014-11-11 |
2018-09-07 |
Medimmune Limited |
包含抗cd73抗体和a2a受体抑制剂的治疗组合及其用途
|
|
CA2971734C
(en)
|
2014-12-22 |
2025-11-18 |
Enumeral Biomedical Holdings Inc |
Anti-pd-1 antibodies
|
|
WO2016109410A2
(en)
|
2014-12-29 |
2016-07-07 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
SG10202111808WA
(en)
|
2015-08-11 |
2021-11-29 |
Novartis Ag |
5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
|
|
WO2017152102A2
(en)
*
|
2016-03-04 |
2017-09-08 |
Alector Llc |
Anti-trem1 antibodies and methods of use thereof
|
|
EP3912681A1
(en)
*
|
2016-03-14 |
2021-11-24 |
Orega Biotech |
Anti-cd39 antibodies
|
|
WO2018013611A1
(en)
|
2016-07-11 |
2018-01-18 |
Corvus Pharmaceuticals, Inc. |
Anti-cd73 antibodies
|
|
SG10202111869SA
(en)
*
|
2017-07-31 |
2021-11-29 |
Trishula Therapeutics Inc |
Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
|
|
CN113754768B
(zh)
|
2018-03-14 |
2023-01-06 |
表面肿瘤学公司 |
结合cd39的抗体及其用途
|
|
EP3927748A1
(en)
*
|
2019-02-21 |
2021-12-29 |
Trishula Therapeutics, Inc. |
Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies
|